The BCL-2-specific BH3-mimetic drug Venetoclax is used for the treatment of patients with CLL and AML, and inhibitors of MCL-1 or BCL-XL have shown efficacy in pre-clinical models but are less advanced clinically [16]. The gene discussed is MCL1; the disease is B-cell chronic lymphocytic leukemia.